Abstract
This study reports a case of unresectable intrahepatic mass-forming cholangiocarcinoma which showed a dramatic response to gemcitabine that led to curative resection and a long-term survival of more than five years. Six and five cycles of gemcitabine monotherapy were administered separately over a three-year period and a radical excision was performed at 4.5 years after diagnosis. This case indicates the role of gemcitabine as a neoadjuvant chemotherapeutic agent for cholangiocarcinoma and guarantees a randomized controlled prospective study.
MeSH terms
-
Antimetabolites, Antineoplastic / therapeutic use*
-
Bile Duct Neoplasms / diagnosis
-
Bile Duct Neoplasms / drug therapy*
-
Bile Duct Neoplasms / surgery
-
Bile Ducts, Intrahepatic / diagnostic imaging
-
Bile Ducts, Intrahepatic / pathology*
-
Cholangiocarcinoma / diagnosis
-
Cholangiocarcinoma / drug therapy*
-
Cholangiocarcinoma / surgery
-
Combined Modality Therapy
-
Deoxycytidine / analogs & derivatives*
-
Deoxycytidine / therapeutic use
-
Female
-
Gemcitabine
-
Humans
-
Middle Aged
-
Neoadjuvant Therapy / methods
-
Radiography
Substances
-
Antimetabolites, Antineoplastic
-
Deoxycytidine
-
Gemcitabine